Soligenix (NASDAQ: SNGX), announced encouraging interim results from their extended HyBryte™ treatment study for early-stage cutaneous T-cell lymphoma (CTCL), funded by a $2.6 million FDA Orphan Products Development Grant. Under the leadership of Dr. Ellen Kim at the University of Pennsylvania, six patients have been treated, with 75% of those completing 12 weeks achieving significant improvement. The study supports HyBryte™'s safety and efficacy, suggesting potential as a long-term treatment option for this rare and challenging disease. Further updates are anticipated as the study progresses.
Disclosure
Soligenix (SNGX) is a client of RedChip Companies, Inc. SNGX agreed to pay RedChip Companies, Inc. 50,000 shares of Rule 144 stock, deemed earned immediately, and a monthly cash fee of $10,000, beginning in April 2023, for 12 months of RedChip investor awareness services. SNGX also agreed to pay RedChip a one-time fifty-thousand dollar fee for a 10 day national TV ad campaign aired June 12 through June 25, 2024.